Home » Stocks » RGCB

Regencell Bioscience Holdings Limited (RGCB)

Regencell Bioscience will go public soon, but the exact IPO date is still unknown.
Stock Price: Pending
IPO price not available yet
Market Cap n/a
Revenue (ttm) n/a
Net Income (ttm) -812,371
Shares Out n/a
EPS (ttm) n/a
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day n/a
Last Price n/a
Previous Close n/a
Change ($) n/a
Change (%) n/a
Day's Open n/a
Day's Range n/a
Day's Volume n/a
52-Week Range n/a

News

Hide News

Regencell Bioscience Holdings, which is developing formulations of traditional Chinese medicine for ADHD and ASD, filed on Monday with the SEC to raise up to $18 million in an initial public offering.

4 weeks ago - NASDAQ

Regencell Bioscience has filed to go public with an IPO on the NASDAQ.

4 weeks ago - SEC

About RGCB

Regencell Bioscience is an early-stage bioscience company that focuses on research, development and commercialization of Traditional Chinese Medicine (\"TCM\") for the treatment of neurocognitive disorders and degeneration, specifically Attention Deficit Hyperactivity Disorder (“ADHD”) and Autism Spectrum Disorder (“ASD”). Our goal is to improve the lives of ADHD and ASD patients, their families and caregivers and become a market leader for the best treatment of ADHD and ASD globally. We have three standardized TCM formulae candidates u... [Read more...]

Industry
Medicinal Chemicals & Botanical Products
IPO Date
Pending
CEO
Yat-Gai Au
Country
Hong Kong
Stock Exchange
NASDAQ
Ticker Symbol
RGCB
Full Company Profile

Financial Performance

Financial Statements